Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF
Reason given: Inadequate treatment response observed in preliminary data did not justify enrolling further study participants
Key facts
- Where
- St John's, Antigua & BarbudaSee the site
- Phase
- Phase 1
Where in Antigua & Barbuda
- Medical Surgical Associates CenterSt John's, Antigua & BarbudaNo longer taking part
Trial details
- Who runs it
- The Foundation for Orthopaedics and Regenerative Medicine
- Trial code
- NCT05016817
- Record updated
- 20 October 2026
- Original description
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Idiopathic pulmonary fibrosisRead full original descriptionShow less
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Idiopathic Pulmonary Fibrosis
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Idiopathic pulmonary fibrosis
Inclusion: Diagnosis of Idiopathic Pulmonary Fibrosis; Understanding and willingness to sign a written informed consent document.
Exclusion: Continued drug abuse; Previous organ transplant; Active infection; Active cancer; Chronic multisystem organ failure; Medical condition that would (based on the opinion of the investigator) compromise patient's safety; Hypersensitivity to sulfur; Clinically significant Abnormalities on pre-treatment laboratory evaluation; Pregnancy; Pre-menopausal women not using contraception.